Daiichi Sankyo Company ($DSKYF) announced an update on their ongoing clinical study. Study OverviewThis study, officially titled “KEYMAKER-U01 ...

Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

The KEYNOTE-905 trial showed significant survival benefits with enfortumab vedotin and pembrolizumab in muscle-invasive bladder cancer, suggesting a new standard for cisplatin-ineligible patients. The ...

Belzutifan, pembrolizumab, and lenvatinib combination showed improved efficacy in advanced ccRCC compared with other regimens. Arm 4 demonstrated a significant median duration of response and ...

Results from sub-study 03A of KEYMAKER-U03, an international, open-label, rolling-arm, phase I/II umbrella trial, spotlight the promise of pembrolizumab-based regimens combined with tyrosine kinase ...

Belzutifan, pembrolizumab, and lenvatinib combination showed superior efficacy in advanced ccRCC, with high overall response rates and prolonged progression-free survival. Arm 4 demonstrated a median ...

Mojo Vision announced it’s secured a $75 million Series B Prime investment round, which the company says will support the commercialization of its powerful and flexible micro-LED platform for XR ...

Thinking back on this epic film franchise has us eager to look back on some of the characters who didn’t stick around as long as we wish they had. Keep reading for five characters from The Matrix ...